29 Oct 2025 | 5 Mins Read
USFDA approves Alembic Pharma's coronary syndrome drug treatment
Flipitmoney
Alembic Pharmaceuticals Ltd. received final USFDA approval for its Ticagrelor tablets, 60mg. The tablets reduce cardiovascular risks in patients with acute coronary syndrome or history of MI. It is therapeutically equivalent to AstraZeneca's Brilinta Tablets. The market size is $236 million, and Alembic Pharma has 206 final ANDA approvals, including 90mg Ticagrelor tablets, approved earlier.